Literature DB >> 7160386

Inhibition of protein glycosylation and selective cytotoxicity toward virally transformed fibroblasts caused by B3-tunicamycin.

D Duksin, M Seiberg, W C Mahoney.   

Abstract

The biological effect of B3-tunicamycin, the only known homologue of tunicamycin which contains a saturated fatty-acid side chain, was examined using chick embryo fibroblasts, a mouse fibroblastic line (3T3) and a virally transformed mouse fibroblastic line (SV40-3T3). This homologue inhibited the transfer of N-acetylglucosamine 1-phosphate from UDP-N-acetylglucosamine to dolichyl phosphate, catalyzed by microsomes from chick liver or from cultured mouse fibroblasts. B3-tunicamycin also inhibited the incorporation of mannose into glycoproteins synthesized by chick or mouse fibroblasts. Incorporation of the amino acids proline and tyrosine was inhibited by B3-tunicamycin to a lesser extent than the incorporation of mannose. The mannose incorporation into glycoproteins synthesized by virally transformed cells was inhibited by B3-tunicamycin to a higher degree than what was achieved in the nontransformed lines or in the chick primary fibroblasts. When the activity of B3-tunicamycin as an inhibitor of protein glycosylation was compared to other homologues of tunicamycin, it was found to be the most active. This homologue caused complete (more than 95%) inhibition of protein glycosylation at a concentration of 50 ng/ml in chick and in mouse fibroblasts and at a concentration of 10 ng/ml in transformed mouse fibroblasts. When the cytotoxic activities of tunicamycin homologues were examined on nontransformed and virally transformed 3T3 cells, it was found that B3-tunicamycin displayed the highest selective cytotoxicity toward the transformed cells. When transformed fibroblasts (10(5) cells/plate) were treated with B3-tunicamycin (100 ng/ml) for 48 h, complete cell death was observed. The viability and the proliferative activity of the nontransformed fibroblast were normal even when treated with concentrations up to 500 ng/ml of B3-tunicamycin. This suggests that B3-tunicamycin may be a suitable candidate for studies of tumor growth in animals.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7160386     DOI: 10.1111/j.1432-1033.1982.tb07022.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

1.  Markedly reduced activity of mutant calcium-sensing receptor with an inserted Alu element from a kindred with familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.

Authors:  M Bai; N Janicic; S Trivedi; S J Quinn; D E Cole; E M Brown; G N Hendy
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

2.  Tunicamycin-induced cell death in the trigeminal ganglion is suppressed by nerve growth factor in the mouse embryo.

Authors:  Hiroyuki Ichikawa; Bing-Ran Zhao; Mitsuhiro Kano; Yoshinaka Shimizu; Toshihiko Suzuki; Ruji Terayama; Saburo Matsuo; Tomosada Sugimoto
Journal:  Cell Mol Neurobiol       Date:  2009-10-17       Impact factor: 5.046

3.  Inhibition of the formation of lipid-linked intermediates in normal and transformed cells by a purified tunicamycin homologue.

Authors:  R Eren; D Duksin
Journal:  Mol Cell Biochem       Date:  1985-05       Impact factor: 3.396

Review 4.  Inhibitors of protein glycosylation and glycoprotein processing in viral systems.

Authors:  R Datema; S Olofsson; P A Romero
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

5.  Adaptive suppression of the ATF4-CHOP branch of the unfolded protein response by toll-like receptor signalling.

Authors:  Connie W Woo; Dongying Cui; Jerry Arellano; Bernhard Dorweiler; Heather Harding; Katherine A Fitzgerald; David Ron; Ira Tabas
Journal:  Nat Cell Biol       Date:  2009-10-25       Impact factor: 28.824

6.  Novel inhibitory action of tunicamycin homologues suggests a role for dynamic protein fatty acylation in growth cone-mediated neurite extension.

Authors:  S I Patterson; J H Skene
Journal:  J Cell Biol       Date:  1994-02       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.